Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors

Area of Science:

• Virology
• Oncology
• Gene Therapy

Background:

• Glioblastoma is a fatal brain malignancy with limited treatment options.
• Herpes simplex virus (HSV) can be engineered into a safe, efficient gene delivery vector.
• Current therapies for glioblastoma have poor prognoses.

Purpose of the Study:

• To develop a novel gene therapy approach for glioblastoma using modified HSV.
• To evaluate the efficacy of combination gene therapy and radiotherapy in preclinical models.

Main Methods:

• Engineering replication-defective herpes simplex virus (HSV) vectors to carry multiple therapeutic transgenes.
• Administering HSV vectors to target glioblastoma cells.
• Combining HSV gene therapy with gamma-knife radiotherapy in animal models.

Main Results:

• Demonstrated successful and efficient delivery of multiple transgenes using HSV vectors.
• Achieved significant ablation of experimental glioblastoma tumors when using combination therapy.
• HSV vectors showed a non-pathogenic profile for gene delivery.

Conclusions:

• Replication-defective HSV vectors offer a promising platform for glioblastoma gene therapy.
• Combination gene therapy with HSV vectors and radiotherapy is an effective strategy against CNS malignancies.
• This approach holds potential for improving outcomes in patients with glioblastoma.